SCHEMBL44676

SCHEMBL44676

O=C(OCC1c2ccccc2-c2ccccc21)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
FABP5 Q01469 3/20 0.56
FABP7 O15540 2/20 0.56
EPHX2 P34913 1/20 0.54
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
HTR2A P28223 1/20 0.47
POLB P06746 1/20 0.44
CASP3 P42574 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15058849 0.92 KMT2A (0.55) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL20903881 0.91 KMT2A (0.51) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL6444593 0.91 KMT2A (0.51) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL29503802 0.90 FABP5 (0.52) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL10263237 0.90 FABP5 (0.52) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL13044481 0.89 KMT2A (0.52) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL17167370 0.89 KMT2A (0.56) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL15119354 0.89 KMT2A (0.60) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL10201861 0.88 KMT2A (0.49) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL15981181 0.88 KMT2A (0.58) KMT2AFABP5FABP7EPHX2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5002 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035402-A1 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF ZIKANI THERAPEUTICS INC (US) 2026-02-05 US claimed
EP-3947382-B1 COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND BETA-THALASSEMIA ACADEMIA SINICA (TW) 2025-09-24 EP claimed
EP-4484439-A1 6'-CYANO-MODIFIED LOCKED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID POLYMER Academy of Military Medical Sciences (CN) 2025-01-01 EP claimed
WO-2024234728-A1 6'-CYANO-MODIFIED LOCKED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID POLYMER 中国人民解放军军事科学院军事医学研究院 2024-11-21 WO claimed
CN-118791543-A Synthesis of 3' -RNA oligonucleotides 阿尔尼拉姆医药品有限公司 2024-10-18 CN claimed
US-12060334-B2 3-substituted phenazine derivatives as antimicrobial agents UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-08-13 US claimed
CN-118369427-A Extrahepatic delivery IRNA compositions and methods of use thereof 阿尔尼拉姆医药品有限公司 2024-07-19 CN claimed
CN-115038790-B Synthesis of 3' -RNA oligonucleotides 阿尔尼拉姆医药品有限公司 2024-06-21 CN claimed
EP-2991655-B1 COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2024-04-10 EP claimed
EP-4337259-A1 COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF Aprinoia Therapeutics Limited (HK) 2024-03-20 EP claimed
EP-1666452-A2 Compounds to treat Alzheimer's disease Elan Pharmaceuticals, Inc. (US) 2006-06-07 EP claimed
EP-1299352-B1 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARM INC (US) 2005-12-28 EP claimed
JP-2004502669-A 2004-01-29 JP claimed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 EP claimed
EP-1299352-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-04-09 EP claimed
US-20030013881-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS, INC. 2003-01-16 US claimed
US-20020128255-A1 Compounds to treat alzheimer's disease PHARMACIA & UPJOHN COMPANY 2002-09-12 US claimed
US-20020016320-A1 Compounds to treat alzheimer's disease ELAN PHARMACEUTICALS, INC. 2002-02-07 US claimed
WO-2002002506-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO claimed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO claimed